Bifogade filer
Vicore to Present at Upcoming Investor Conferences
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Small Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Stockholm, November 14, 2024 - Vicore Pharma Holding AB (STO: VICO), unlocking the potential of a novel class of drug candidates, angiotensin II type 2 receptor agonists (ATRAGs), today announced participation in the following investor conferences:
- Stifel 2024 Healthcare Conference
Location: New York, United States
Presenter: Ahmed Mousa, CEO
Presentation Date and Time: November 18 at 9:10 AM ET/3:10 PM CET
Webcast: https://wsw.com/webcast/stifel96/vico/2103734
- SEB Healthcare Seminar
Location: Stockholm, Sweden
Presenter: Hans Jeppsson, CFO
Presentation Date and Time: November 20 at 4:40 AM ET/10:40 AM CET
- DNB Nordic Healthcare Conference
Location: Oslo, Norway
Presenter: Hans Jeppsson, CFO
Presentation Date and Time: November 26 at 10:15 AM ET/4:15 PM CET
For further information, please contact:
Megan Richards, VP of IR, Communications, and Portfolio Strategy, tel: +1 978 269-4372, megan.richards@vicorepharma.com
Hans Jeppsson, CFO, tel: +46 70 553 14 65, hans.jeppsson@vicorepharma.com
This information was submitted for publication on November 14, 2024, at 8:00 CET.
About Vicore Pharma Holding AB
Vicore is a clinical-stage pharmaceutical company unlocking the potential of a new class of drugs with disease-modifying potential. The company is advancing a portfolio of therapies in respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). Buloxibutid (C21) is a first-in-class orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) being investigated in a global Phase 2b trial in IPF. Almee™ is an investigational digital therapeutic in clinical development that is based on cognitive behavioral therapy and created to address the psychological impact of living with pulmonary fibrosis. Almee has received Breakthrough Device Designation from the FDA, which the Company believes reflects its potential to have transformative impact. Using its expertise in ATRAG chemistry and biology, Vicore is further developing its pipeline with several new therapies across additional indications. The company’s shares are listed on Nasdaq Stockholm’s main market (VICO). www.vicorepharma.com